MarketCap
Facebook
X
Telegram
Teladoc Health Deferred Revenue | TDOC
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Teladoc Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.3 M | 79.3 M | 95.7 M | 90.5 M | 75.6 M | 65.8 M | 12.5 M | 7.65 M | 4.11 M | 1 M | 831 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.7 M | 831 K | 45 M |
Quarterly Deferred Revenue Teladoc Health
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.8 M | 65.7 M | 70.1 M | 74.7 M | 73.9 M | 79.3 M | 88.3 M | 95.4 M | 101 M | 95.7 M | 99.2 M | 107 M | 95.9 M | 102 M | 90.2 M | - | 83.8 M | 75.6 M | 72.9 M | 69.3 M | 70.5 M | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 12.5 M | 12.5 M | 12.3 M | 12.5 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 4.11 M | 3.52 M | 2.41 M | 1.62 M | 1 M | 1 M | 1 M | 1 M | 831 K | 831 K | 831 K | 831 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 107 M | 831 K | 45 M |
Deferred Revenue of other stocks in the Health information services industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Omnicell
OMCL
|
172 M | $ 34.64 | 3.1 % | $ 1.59 B |  USA |
 |
OptimizeRx Corporation
OPRX
|
503 K | $ 8.72 | 1.75 % | $ 162 M | USA |
 |
Phreesia
PHR
|
49.5 M | $ 10.37 | 2.88 % | $ 619 M | USA |
 |
Schrödinger
SDGR
|
113 M | $ 32.6 | 7.56 % | $ 2.39 B | USA |
 |
So-Young International
SY
|
65.9 M | $ 2.74 | 0.36 % | $ 213 M |  China |
 |
10x Genomics
TXG
|
23.9 M | $ 97.74 | 4.53 % | $ 12.2 B | USA |
 |
Veeva Systems
VEEV
|
1.49 B | $ 283.45 | 3.7 % | $ 46.4 B | USA |
 |
Zhongchao
ZCMD
|
150 K | $ 1.91 | 3.24 % | $ 6.53 M | China |
 |
NantHealth
NH
|
2.72 M | - | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
15 M | - | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
49.8 M | - | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
14 M | - | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
469 M | - | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
2.4 M | - | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
3.2 M | - | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
531 M | - | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
3.86 M | - | - | $ 102 M | USA |
 |
NextGen Healthcare
NXGN
|
61.6 M | - | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
34.8 M | - | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
121 M | - | -10.39 % | $ 886 M | USA |
 |
Castlight Health, Inc.
CSLT
|
6.85 M | - | -7.28 % | $ 227 M | USA |
 |
Inovalon Holdings, Inc.
INOV
|
10.9 M | - | - | $ 6.37 B | USA |
 |
Computer Programs and Systems
CPSI
|
9.21 M | - | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
400 K | - | - | $ 161 M | USA |
 |
MTBC
MTBC
|
4.15 M | - | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
22.5 M | - | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
6.1 M | - | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
159 K | - | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
22.6 M | $ 12.72 | 2.66 % | $ 204 M | USA |
 |
Evolent Health
EVH
|
1.2 M | $ 3.61 | 4.34 % | $ 412 M | USA |
 |
GoodRx Holdings
GDRX
|
6.7 M | $ 3.36 | 2.44 % | $ 1.2 B | USA |
 |
Health Catalyst
HCAT
|
56.1 M | $ 1.76 | 0.57 % | $ 123 M | USA |
 |
HealthStream
HSTM
|
88.4 M | $ 31.54 | 2.34 % | $ 947 M | USA |